1. Home
  2. NCMI vs ALXO Comparison

NCMI vs ALXO Comparison

Compare NCMI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

N/A

Current Price

$1.59

Market Cap

207.0M

ML Signal

N/A

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

N/A

Current Price

$1.16

Market Cap

172.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCMI
ALXO
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
207.0M
172.8M
IPO Year
2006
2020

Fundamental Metrics

Financial Performance
Metric
NCMI
ALXO
Price
$1.59
$1.16
Analyst Decision
Buy
Strong Buy
Analyst Count
4
7
Target Price
$4.44
★ $4.60
AVG Volume (30 Days)
621.4K
★ 1.5M
Earning Date
11-10-2026
11-17-2026
Dividend Yield
★ 5.56%
N/A
EPS Growth
★ 52.17
26.36
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
$9.27
N/A
Revenue Next Year
$2.48
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.43
$0.86
52 Week High
$4.34
$2.66

Technical Indicators

Market Signals
Indicator
NCMI
ALXO
Relative Strength Index (RSI) 28.85 40.24
Support Level N/A $1.03
Resistance Level $2.30 $1.30
Average True Range (ATR) 0.10 0.14
MACD -0.01 0.02
Stochastic Oscillator 26.47 5.13

Price Performance

Historical Comparison
NCMI
ALXO

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: